Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Candyce Kroenke and Lawrence Kushi.
Connection Strength

5.162
  1. Social Support and Treatment Delays in Breast Cancer Patients Within an Integrated Health Care System. Psychooncology. 2024 Nov; 33(11):e70025.
    View in: PubMed
    Score: 0.881
  2. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Breast Cancer Res Treat. 2018 Aug; 170(3):623-631.
    View in: PubMed
    Score: 0.560
  3. Social networks, social support mechanisms, and quality of life after breast cancer diagnosis. Breast Cancer Res Treat. 2013 Jun; 139(2):515-27.
    View in: PubMed
    Score: 0.398
  4. Development and Validation of a Natural Language Processing Algorithm Using Electronic Health Record Data to Identify Breast Cancer Patients With Low Social Support. JCO Oncol Adv. 2025 Dec; 2(1).
    View in: PubMed
    Score: 0.237
  5. Evaluation of the Electronic Health Record-Support Social Support Score in Breast Cancer: Comparison of Count and Item Response Theory Scores. Popul Health Manag. 2025 12; 28(6):273-280.
    View in: PubMed
    Score: 0.235
  6. Associations Between Immigrant Status and Dietary Patterns in ENCLAVE, A Pooled, Observational Study of Women Diagnosed With Breast Cancer. J Nutr. 2025 Jun 30.
    View in: PubMed
    Score: 0.231
  7. Nativity and Healthy Lifestyle Index in a Pooled Cohort of Female Breast Cancer Survivors from Northern California. Cancer Epidemiol Biomarkers Prev. 2025 May 07.
    View in: PubMed
    Score: 0.228
  8. A validation study for measuring Asian- and Hispanic-serving sociocultural institutions in neighborhoods using business listing data and potential implications for health. Soc Sci Med. 2024 Jul 17; 356:117143.
    View in: PubMed
    Score: 0.216
  9. Differences in Smoking Behavior by Nativity, Race/Ethnicity, and Education Among Women Diagnosed with Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2024 Feb 12.
    View in: PubMed
    Score: 0.210
  10. Individual- and neighborhood-level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California. Cancer. 2021 Aug 20.
    View in: PubMed
    Score: 0.177
  11. Clustering of Social and Physical Pain Variables and Their Association With Mortality in Two Population-Based Cohorts. Psychosom Med. 2021 04 01; 83(3):228-238.
    View in: PubMed
    Score: 0.172
  12. "I Had to Make Them Feel at Ease": Narrative Accounts of How Women With Breast Cancer Navigate Social Support. Qual Health Res. 2021 05; 31(6):1056-1068.
    View in: PubMed
    Score: 0.171
  13. Representativeness of breast cancer cases in an integrated health care delivery system. BMC Cancer. 2015 Oct 14; 15:688.
    View in: PubMed
    Score: 0.118
  14. Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat. 2014 Apr; 144(3):689-99.
    View in: PubMed
    Score: 0.105
  15. Response to Yu, Wang, and Ge. J Natl Cancer Inst. 2026 Jul 01; 118(7):1332-1333.
    View in: PubMed
    Score: 0.062
  16. Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast?cancer. J Natl Cancer Inst. 2026 Jul 01; 118(7):1278-1289.
    View in: PubMed
    Score: 0.062
  17. The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer. Cancer. 2026 Mar 15; 132(6):e70318.
    View in: PubMed
    Score: 0.061
  18. Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer. Cancer. 2026 Mar 01; 132(5):e70294.
    View in: PubMed
    Score: 0.060
  19. Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer. J Natl Cancer Inst. 2026 Feb 01; 118(2):307-315.
    View in: PubMed
    Score: 0.060
  20. Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer. JCO Oncol Pract. 2025 Dec 11; OP2500086.
    View in: PubMed
    Score: 0.059
  21. Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settings. Int J Cancer. 2026 Mar 15; 158(6):1481-1488.
    View in: PubMed
    Score: 0.059
  22. Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer. NPJ Breast Cancer. 2025 Oct 29; 11(1):119.
    View in: PubMed
    Score: 0.059
  23. Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancer. Breast Cancer Res Treat. 2025 Aug; 213(1):115-126.
    View in: PubMed
    Score: 0.058
  24. Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancer. Int J Cancer. 2025 Jun 02.
    View in: PubMed
    Score: 0.057
  25. Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study. JCO Clin Cancer Inform. 2025 Feb; 9:e2400231.
    View in: PubMed
    Score: 0.056
  26. The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system. Breast Cancer Res Treat. 2024 Nov; 208(2):405-414.
    View in: PubMed
    Score: 0.054
  27. Patient characteristics associated with intended non-guideline chemotherapy in women with stage I-IIIA breast cancer. Cancer Epidemiol Biomarkers Prev. 2024 Jul 25.
    View in: PubMed
    Score: 0.054
  28. Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer. Int J Cancer. 2024 Jul 06.
    View in: PubMed
    Score: 0.054
  29. Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019. Breast Cancer Res. 2024 Jun 13; 26(1):101.
    View in: PubMed
    Score: 0.054
  30. Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast Cancer. JCO Clin Cancer Inform. 2024 Apr; 8:e2300209.
    View in: PubMed
    Score: 0.053
  31. Evaluation of algorithms using automated health plan data to identify breast cancer recurrences. Cancer Epidemiol Biomarkers Prev. 2023 Dec 13.
    View in: PubMed
    Score: 0.052
  32. Impact of Racial/Ethnic Discrimination on Quality of Life among Breast Cancer Survivors: The Pathways Study. Am J Epidemiol. 2022 Dec 01.
    View in: PubMed
    Score: 0.048
  33. Impact of Social and Built Environment Factors on Body Size among Breast Cancer Survivors: The Pathways Study. Cancer Epidemiol Biomarkers Prev. 2017 04; 26(4):505-515.
    View in: PubMed
    Score: 0.032
  34. Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer Res. 2016 09 15; 76(18):5415-22.
    View in: PubMed
    Score: 0.031
  35. Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer. J Clin Oncol. 2016 08 10; 34(23):2743-9.
    View in: PubMed
    Score: 0.031
  36. Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival. J Natl Cancer Inst. 2015 Jul; 107(7).
    View in: PubMed
    Score: 0.028
  37. Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer. 2015 Apr 14; 15:278.
    View in: PubMed
    Score: 0.028
  38. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):725-34.
    View in: PubMed
    Score: 0.026
  39. Racial disparities in posttraumatic stress after diagnosis of localized breast cancer: the BQUAL study. J Natl Cancer Inst. 2013 Apr 17; 105(8):563-72.
    View in: PubMed
    Score: 0.024

© 2026 Kaiser Permanente

Your Privacy Choices